相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
C. F. Deacon
DIABETES OBESITY & METABOLISM (2011)
Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes
R. R. Henry et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2011)
Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial
J. E. Foley et al.
DIABETOLOGIA (2011)
Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice
Aurelie Waget et al.
ENDOCRINOLOGY (2011)
The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats
Alokesh Duttaroy et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Emerging treatment options for type 2 diabetes
Milan K. Piya et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
Kristine J. Hare et al.
DIABETES (2010)
Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Bo Ahren et al.
DIABETES CARE (2010)
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Carolyn F. Deacon et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
Bo Ahren
Diabetes Metabolic Syndrome and Obesity-Targets and Therapy (2010)
Saxagliptin for type 2 diabetes
Antonio R. Chacra
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2010)
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Carolyn F. Deacon et al.
ADVANCES IN THERAPY (2009)
Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis
Daniel M. Riche et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2009)
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes
James Mu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Richard E. Pratley
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes
Bo Ahren et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes
David A. D'Alessio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database
R. E. Pratley et al.
DIABETES OBESITY & METABOLISM (2008)
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia
W. A. Scherbaum et al.
DIABETES OBESITY & METABOLISM (2008)
The islet enhancer vildagliptin: mechanisms of improved glucose metabolism
B. Ahren et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes
Koichiro Azuma et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
Leo Thomas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion
Andrea El-Ouaghlidi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Improved meal-related insulin processing contributes to the enhancement of B-Cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes
B. Ahren et al.
HORMONE AND METABOLIC RESEARCH (2007)
DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with non-nalized islet topography in mice with β-cell-specific overexpression of human islet amylold polypeptide
Bo Ahren et al.
REGULATORY PEPTIDES (2007)
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
V. Fonseca et al.
DIABETOLOGIA (2007)
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT
Yan-Ling He et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
Bogdan Balas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Maire E. Doyle et al.
PHARMACOLOGY & THERAPEUTICS (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
Gary A. Herman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Julio Rosenstock et al.
CLINICAL THERAPEUTICS (2006)
Vildagliptin:: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties
B Ahrén
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
Beta-cell expression of a dominant-negative HNF-1α compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice
B Ahrén et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes
A Mari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
B Ahrén et al.
DIABETES CARE (2005)
Type 2 diabetes, insulin secretion and β-cell mass
B Ahrén
CURRENT MOLECULAR MEDICINE (2005)
Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice
B Ahrén et al.
ENDOCRINOLOGY (2005)
Alpha cell function in health and disease: influence of glucagon-like peptide-1
BE Dunning et al.
DIABETOLOGIA (2005)
Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors
T Hansotia et al.
DIABETES (2004)
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
B Ahrén et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice
B Ahrén
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2004)
The high-fat diet-fed mouse -: A model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes
MS Winzell et al.
DIABETES (2004)
The role of GLP-1 in the life and death of pancreatic beta cells
R Perfetti et al.
HORMONE AND METABOLIC RESEARCH (2004)
Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
JJ Meier et al.
DIABETOLOGIA (2003)
Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats
JA Pospisilik et al.
DIABETES (2003)
Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice
MK Reimer et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
B Ahrén et al.
DIABETES CARE (2002)
Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion
AM Lambeir et al.
FEBS LETTERS (2001)
Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
B Ahrén et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
分享论文
